Ovarian aging: from mechanism to translation

Reproductive aging is a complex biological process, characterized by infertility, hormonal perturbations and metabolic dysregulations. Medical advances have enabled the increase of life expectancy; however, menopause still occurs at the age of 50. After menopause, ovarian-synthesized estradiol levels decrease, affecting the reproductive system functionality as well as many other downstream organs, such as the bones (osteoporosis). The development of new approaches to delay reproductive aging will not only enhance reproductive longevity but will also pause the appearance of reproductive age-associated diseases. So far, most research on reproductive aging infertility has focused on the reduction in the oocyte quantity and quality. Less attention has been given to the environment in which oocytes develop, the ovarian stroma. We recently found that with age the ovary assumes a pro-inflammatory, pro-fibrotic and stiff environment affecting oocyte quality and ovulation. We are currently developing a preclinical pipeline using mice to test the treatment-efficacy of anti-fibrotic and anti-inflammatory drugs in delaying reproductive aging and improving health span.